Research programme: antimetastatic therapeutics - SupratekAlternative Names: SP-MET-1; SP-MET-2; SP-MET-X1; SP-MET-X2
Latest Information Update: 28 Nov 2007
At a glance
- Originator Supratek Pharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Nov 2007 Preclinical development is ongoing
- 30 Jun 2005 Preclinical trials in Cancer in Canada (PO)